Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tumor lysis syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Tumor lysis syndrome. Displaying page 1 of 1.
    EudraCT Number: 2012-000776-42 Sponsor Protocol Number: FLO-01 Start Date*: 2012-09-17
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study versus Allopurinol
    Medical condition: Tumor Lysis Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045170 Tumour lysis syndrome PT
    14.1 10027433 - Metabolism and nutrition disorders 10045152 Tumor lysis syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001445-61 Sponsor Protocol Number: FLO-02 Start Date*: 2016-09-12
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Open label, multi-centre, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety of febuxostat between pediatric patients (≥6<18 years of age) and adults.
    Medical condition: Hematological malignancies at intermediate to high risk of Tumor Lysis Syndrome ( TLS) prevention.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10045170 Tumour lysis syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003989-24 Sponsor Protocol Number: L_9436 Start Date*: 2014-12-19
    Sponsor Name:Sanofi
    Full Title: Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001777-25 Sponsor Protocol Number: FILOCLL09-IDA53 Start Date*: 2018-10-02
    Sponsor Name:FILO
    Full Title: A Phase II Pilot Study to Evaluate the Safety and Efficacy of the association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction. IDA53 trial
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003176-14 Sponsor Protocol Number: LPS15679 Start Date*: 2021-06-29
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin...
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000087-29 Sponsor Protocol Number: MO28543 Start Date*: 2013-08-26
    Sponsor Name:F. Hoffmann- La Roche Ltd.
    Full Title: A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relap...
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    16.0 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) FI (Completed) LV (Completed) SI (Completed) IE (Completed) PT (Completed) EE (Completed) GR (Completed) SE (Completed) PL (Completed) SK (Completed) BE (Completed) LT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003740-13 Sponsor Protocol Number: RC14_0048 Start Date*: 2015-09-11
    Sponsor Name:CHU de Nantes
    Full Title: A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients -OAsIs
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004555-16 Sponsor Protocol Number: M20-429 Start Date*: 2022-04-25
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
    Medical condition: Relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, Diffuse large B-cell lymphoma , or other aggressive mature (CD20+) B-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10006596 Burkitt's lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011225-14 Sponsor Protocol Number: Le.P.Re. Study Start Date*: 2009-05-22
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
    Medical condition: Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia, [Hallek M et al, 2008]).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000129-12 Sponsor Protocol Number: PCYC-1143-CA Start Date*: 2017-10-10
    Sponsor Name:Pharmacyclics LLC
    Full Title: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) BE (Completed) HU (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003409-23 Sponsor Protocol Number: MERMAID1 Start Date*: 2023-12-12
    Sponsor Name:Medical University of Warsaw
    Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I...
    Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004613-14 Sponsor Protocol Number: VERITA_PALG-CLL5 Start Date*: 2021-10-31
    Sponsor Name:POLISH ADULT LEUKEMIA GROUP
    Full Title: A prospective, multicenter, phase II trial to assess the efficacy and safety of MRD-driven treatment with VEnetoclax and RItuximab combination in previously unTreated pAtients with chronic lymphocy...
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001573-89 Sponsor Protocol Number: D8220C00008 Start Date*: 2019-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) FI (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 04:30:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA